Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effectiveness and safety of Apidra plus Lantus in basal–bolus regimen in children and adolescents with type 1 diabetes in Russia
2014-004639-38Phase 4
- Sponsor
- Sanofi
- Start
- Apr 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4 trial of human insulin and insulin glargine in diabetes mellitus type 1 (T1D) (2 arms), sponsored by Sanofi. Primary endpoints: Percentage of patients achieving HbA1c target at 6 months and Percentage of patients achieving HbA1c target at 12 months.
02
Drugs
human insulininsulin glargine
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2014-004639-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004639-38.